In vitro selection of HIV-1 resistance of ddI is not as efficient as for other antiretroviral drugs and yields virus which shows reduced cytophatic activity

Abstract

The locations of HIV-1 RT nucleoside and non-nucleoside inhibitor-binding sites and inhibitor-resistance mutations are analyzed in the context of the three-dimensional structure of the enzyme and implications for mechanisms of drug inhibition and resistance are discussed. In order to help identify residues that may play a role in inhibitor binding, solvent accessibilities of amino acids that comprise the inhibitor-binding sites in the structure of HIV-1 RT complexed with a dsDNA template-primer are analyzed. While some mutations that cause resistance to nucleoside analogs, such as AZT, ddI, and ddC, are located near enough to the dNTP-binding site to direct interfere with binding of nucleoside analogs many are located away from the DNTP-binding site and more likely confer resistance by other mechanisms. Many of the latter mutations are located on the surface of the DNA-binding cleft and may lead to altered template-primer positioning or conformation, causing a distortion of the geometry of the polymerase active site and consequent discrimination between normal and altered DNTP substrates. Other nucleoside analog-resistance mutations located on the periphery of the DNTP-binding site may exert their effects via altered interactions with DNTP-binding site residues. The structure of the hydrophobic region in HIV-1 RT that binds non-nucleoside inhibitors, for example, nevirapine and TIBO, has been analyzed in the absence of bound ligand. The pocket that is present when non-nucleoside inhibitors are bond is not observed in the inhibitor-free structure of HIV-1 RT with dsdna. In particular it is filled by Tyr181 and Tyr188, suggesting that the pocket is formed primarily by rotation of these large aromatic side-chains. Existing biochemical data, taken together with the three-dimensional structure of HIV-1 RT, makes it possible to propose potential mechanisms of inhibition by non-nucleoside inhibitors. One such mechanism is local distortion of HIV-1 RT structural elements thought to participate in catalysis: the β9-β10 hairpin (which contains polymerase active site residues) and the β12-β13 hairpin ("primer grip"). An alternative possibility is restricted mobility of the p66 thumb subdomain, which is supported by the observation that structural elements of the non-nucleoside inhibitor-binding pocket may act as a "hinge" for the thumb. Mutations that have been shown to confer resistance to non-nucleoside inhibitors are observed to cluster around the pocket, suggesting that most of these resistance mutations lead to direct alteration of inhibitor binding. A comparison of residues in the non-nucleoside inhibitor-binding pocket of HIV-1 RT and the corresponding residues in HIV-2 RT can explain the low activity of non-nucleoside compounds against HIV-2 RT.